Home › Funds › Prosight Management, LP › GENB
Prosight Management, LP position in GENB
GENERATE BIOMEDICINES INC · Health Care
Prosight Management, LP reported holding 144,756 shares of GENB (GENERATE BIOMEDICINES INC) in its Q3 2026 13F filing — a position valued at US$2.2M, representing 0.42% of its reported portfolio and ranking #24 among its reported holdings. Prosight Management, LP first reported this position in Q3 2026.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Prosight Management, LP's GENB position evolved
Prosight Management, LP first disclosed a stake in GENB in Q3 2026 at 144,756 shares (US$2.2M).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2026 | 144.76K | $2.17M | New |
About GENB and 13F data
GENB (GENERATE BIOMEDICINES INC) is a Health Care company. 105 other funds we track also report a position in GENB — the largest reported positions include Flagship Pioneering, LLC (US$1.06B), BRAIDWELL LP (US$55.4M), ARCH Venture Management, LLC (US$32.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding GENB
- Flagship Pioneering, LLC 62.67M sh · $1.06B · Q2 2026
- BRAIDWELL LP 3.28M sh · $55.40M · Q2 2026
- ARCH Venture Management, LLC 1.94M sh · $32.80M · Q2 2026
- HARBOURVEST PARTNERS LLC 1.72M sh · $29.05M · Q2 2026
- BANQUE PICTET & CIE SA 1.77M sh · $26.63M · Q3 2026
- Harvard Management Company 1.11M sh · $18.74M · Q2 2026
- NVIDIA CORP 833.33K sh · $14.06M · Q2 2026
- Davern Capital Partners, LP 824.68K sh · $12.39M · Q3 2026
- PICTET BANK & TRUST Ltd 16.67K sh · $250.32K · Q3 2026
More on Prosight Management, LP
FAQ
How long has Prosight Management, LP held GENB?
Prosight Management, LP has disclosed GENB holdings in 1 of the last 1 reported quarters, going back to Q3 2026.
What is Prosight Management, LP's current position in GENB?
As of Q3 2026, Prosight Management, LP holds 144.76K shares of GENB (GENERATE BIOMEDICINES INC), valued at $2.17M, representing 0.42% of its reported portfolio and ranking #24.
Has Prosight Management, LP been buying or selling GENB?
In the latest 13F filing (Q3 2026), Prosight Management, LP newly opened its position in GENB.
Which other funds hold GENB?
Other major institutional holders of GENB include Flagship Pioneering, LLC, BRAIDWELL LP, ARCH Venture Management, LLC, among 105 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.